Ligand Pharmaceuticals Incorporated
LGND
$294.60
$5.782.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 900.78% | 68.56% | 244.06% | 1,735.15% | 109.34% |
| Total Depreciation and Amortization | -3.60% | -6.32% | -4.79% | -8.06% | -3.74% |
| Total Amortization of Deferred Charges | 142.64% | 81.33% | 40.65% | 30.98% | -10.50% |
| Total Other Non-Cash Items | -434.91% | 267.43% | -145.14% | -482.30% | -87.28% |
| Change in Net Operating Assets | -13.45% | 213.87% | -19.94% | -249.07% | 18.91% |
| Cash from Operations | 52.02% | 291.36% | 61.27% | -64.17% | 18.66% |
| Capital Expenditure | 87.85% | -6.54% | 98.74% | 97.48% | 47.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3,172.26% | -1,942.58% | 73.60% | -669.82% | 80.77% |
| Cash from Investing | 3,110.38% | -2,027.81% | 53.13% | -659.98% | 80.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2,797,000.00% | 0.00% | -16.67% | -1,132,460.00% | -75.00% |
| Issuance of Common Stock | 4.39% | 81.29% | -58.58% | -53.56% | -13.75% |
| Repurchase of Common Stock | -41,517.24% | -144.40% | 82.22% | -12,075.20% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,260.38% | 29.58% | -422.88% | 25,041.90% | 12,219.30% |
| Cash from Financing | 3,544.11% | -197.72% | -59.14% | 643.73% | 57.99% |
| Foreign Exchange rate Adjustments | -98.30% | -104.16% | 61.89% | -206.10% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,430.53% | -146.04% | 309.20% | 57.67% | 161.59% |